BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 21518826)

  • 1. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.
    Cox IJ; Aliev AE; Crossey MM; Dawood M; Al-Mahtab M; Akbar SM; Rahman S; Riva A; Williams R; Taylor-Robinson SD
    World J Gastroenterol; 2016 Apr; 22(16):4191-200. PubMed ID: 27122669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Han J; Qin WX; Li ZL; Xu AJ; Xing H; Wu H; Zhang H; Wang MD; Li C; Liang L; Quan B; Yan WT; Shen F; Wu MC; Yang T
    Clin Chim Acta; 2019 Jan; 488():68-75. PubMed ID: 30389456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
    Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
    Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans.
    Ladep NG; Dona AC; Lewis MR; Crossey MM; Lemoine M; Okeke E; Shimakawa Y; Duguru M; Njai HF; Fye HK; Taal M; Chetwood J; Kasstan B; Khan SA; Garside DA; Wijeyesekera A; Thillainayagam AV; Banwat E; Thursz MR; Nicholson JK; Njie R; Holmes E; Taylor-Robinson SD
    Hepatology; 2014 Oct; 60(4):1291-301. PubMed ID: 24923488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
    Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
    Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
    Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis.
    Tan Y; Yin P; Tang L; Xing W; Huang Q; Cao D; Zhao X; Wang W; Lu X; Xu Z; Wang H; Xu G
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.010694. PubMed ID: 22084000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma.
    Comunale MA; Wang M; Rodemich-Betesh L; Hafner J; Lamontagne A; Klein A; Marrero J; Di Bisceglie AM; Gish R; Block T; Mehta A
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1222-9. PubMed ID: 21467232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection.
    Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z
    Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Jirun P; Zhang G; Kim HK; Ha SA; Zhongtian J; Shishi Q; Zhuqingqing C; Lei G; Yoo J; Kim S; Park YG; Wang J; Yang Y; Xu Z; Huang Z; Lee YK; Song EY; Kim JW
    Dis Markers; 2011; 30(6):307-15. PubMed ID: 21725159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.
    Sun Y; Gao G; Cai J; Wang Y; Qu X; He L; Liu F; Zhang Y; Lin K; Ma S; Yang X; Qian X; Zhao X
    Carcinogenesis; 2013 Mar; 34(3):595-604. PubMed ID: 23188673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study.
    Lee CW; Yu MC; Lin G; Chiu JC; Chiang MH; Sung CM; Hsieh YC; Kuo T; Lin CY; Tsai HI
    World J Surg Oncol; 2020 Jun; 18(1):121. PubMed ID: 32493393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Metabolomics Study of the Bile Acid Pathway During Perioperative Primary Hepatic Carcinoma Following Liver Transplantation.
    Sui W; Gan Q; Liu F; Ou M; Wang B; Liao S; Lai L; Chen H; Yang M; Dai Y
    Ann Transplant; 2020 Jun; 25():e921844. PubMed ID: 32572018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.